このコンテンツを視聴するには、JoVE 購読が必要です。 サインイン又は無料トライアルを申し込む。
Method Article
* これらの著者は同等に貢献しました
The current report summarizes a protocol that can be utilized to model the influence of the bone marrow microenvironment niche on leukemic cells with emphasis placed on enrichment of the most chemoresistant subpopulation.
It is well established that the bone marrow microenvironment provides a unique site of sanctuary for hematopoietic diseases that both initiate and progress in this site. The model presented in the current report utilizes human primary bone marrow stromal cells and osteoblasts as two representative cell types from the marrow niche that influence tumor cell phenotype. The in vitro co-culture conditions described for human leukemic cells with these primary niche components support the generation of a chemoresistant subpopulation of tumor cells that can be efficiently recovered from culture for analysis by diverse techniques. A strict feeding schedule to prevent nutrient fluxes followed by gel type 10 cross-linked dextran (G10) particles recovery of the population of tumor cells that have migrated beneath the adherent bone marrow stromal cells (BMSC) or osteoblasts (OB) generating a "phase dim" (PD) population of tumor cells, provides a consistent source of purified therapy resistant leukemic cells. This clinically relevant population of tumor cells can be evaluated by standard methods to investigate apoptotic, metabolic, and cell cycle regulatory pathways as well as providing a more rigorous target in which to test novel therapeutic strategies prior to pre-clinical investigations targeted at minimal residual disease.
The overall goal of the method described is to provide an efficient, cost-effective in vitro approach that supports investigation of the mechanisms that underlie bone marrow supported survival of leukemic cells during chemotherapy exposure. It is well documented that surviving residual tumor cells that persist after treatment contribute to relapse of disease that is often more aggressive than that at diagnosis and is often less effectively treated1-8. Models that include leukemic cells in isolation, such as those limited to culture of cells in media alone, for testing of therapeutic approaches do not factor in these critical signals, or the heterogeneity of disease that occurs in response to availability of niche derived cues in which tumor cell subpopulations with very specific interactions with niche cells derive enhanced protection. Standard 2D co-culture models that co-culture bone marrow derived stromal cells and leukemic cells have somewhat addressed the contribution of the marrow niche and have shown that interaction with bone marrow microenvironment cells increases their resistance to chemotherapy and alters their growth characteristics9-14. These models however often fail to recapitulate long term survival of tumor cells and do not accurately inform the outcomes associated with the most resistant leukemic cell populations that contribute to MRD. In vivo models remain critical and define the "gold standard" for investigation of innovative therapies prior to clinical trials but they are often challenged by the time and cost required to test hypotheses related to resistant tumors and relapse of disease. As such, development of more informative 2D models would be of benefit for pilot investigations to better inform the design of subsequent murine based pre-clinical design.
The 2D in vitro model presented in this report lacks the complexity of the true in vivo microenvironment, but provides a cost effective and reproducible means to interrogate tumor interactions with the microenvironment that lends itself specifically to enrichment of the chemoresistant subpopulation of tumor cells. This distinction is valuable as evaluation of the entire population of tumor cells may mask the phenotype of a minor group of therapy resistant tumor cells that comprise the most important target. An additional advantage is the scalability of the model to fit the analysis of interest. Bulk cultures can be established for those analyses requiring significant recovery of tumor cells, while small scale co-cultures in multi-well plates can be utilized for PCR based analysis or microscopy based evaluations.
Based on this need we developed an in vitro model to address the heterogeneity of disease that is characteristic of B-lineage acute lymphoblastic leukemia (ALL). We demonstrate that ALL cells, which share many characteristics in common with their healthy counterparts, localize to distinct compartments of BMSC or OB co-culture. Three populations of tumor cells are generated that have distinct phenotypes that are valuable for investigation of therapeutic response. Specifically, we demonstrate that (ALL) cells recovered from the "phase dim" (PD) population of co-culture are consistently refractory to therapy with survival that approximates tumor cells that have not been exposed to cytotoxic agents. These ALL cells, from either established cell lines or primary patient samples, migrate beneath adherent stromal cells or osteoblast layers but can be captured following trypsinization of cultures and separation of cell types by utilization of gel type 10 cross-linked dextran (G10) particle columns15.
Here we present a setup of a 2D co-culture that can be employed to model interactions between bone marrow microenvironment stromal cells (BMSC/OB) and leukemic cells. Of particular importance is the observation that leukemic cells form three spatial subpopulations relative to the stromal cell monolayer and that the PD population represents a chemotherapy resistant tumor population due to its interaction with the BMSC or OB. Furthermore, we demonstrate how to effectively isolate the leukemic cell populations by G10 columns. Of note, we have found that isolation of these subpopulations allows for downstream analysis of the most resistant PD population to determine potential modes of resistance that are conferred to these cells due to their interaction with the bone marrow microenvironment stromal cells or osteoblasts. Techniques that we have utilized downstream of this co-culture and isolation model include flow cytometric evaluation, proteomic analysis and targeted protein expression evaluation as well as more recently developed laser ablation electrospray ionization (LAESI) and Seahorse analysis to evaluate metabolic profiles. Through use of this model in combination with the techniques above we have found that the PD population of leukemic cells has a chemotherapy resistant phenotype that is unique when compared to leukemic cells cultured in media alone or those recovered from the other subpopulations in the same co-culture. As such, this model lends itself to more rigorous evaluation to test strategies targeting the most chemotherapy resistant leukemic cells which derive their resistant phenotype through interaction with the bone marrow microenvironment.
1.高度な準備
2.共培養の確立と維持
3.準備G10ビーズカラム
注:次の手順は、無菌テクニックとG10カラムを用いて行われるべきである無菌下流の分析や培養が必要な場合は、次のG10カラム分離は、無菌の生物学的フードでセットアップする必要があります。
4.共培養内の3亜集団を分離
G10カラムに5読み込んで共培養細胞
注:必ずコックはG10カラムに細胞を含む培地を添加する前に完全に閉じていることを確認します。また、それぞれの亜集団はintroducしないよう個別のG10カラム上で実行する必要があります下流の分析における集団間の偏りを電子。
6. G10カラムから白血病細胞を収集
この共培養モデルの成功セットアップと文化が。付着BMSC又はOB単層に比べて白血病細胞の3亜集団の確立につながる1は、BMSCの単層に播種ALL細胞は、最初に中断のようにのみ単一集団をどのように表示されるかを示しています白血病細胞。 4日間のコースで白血病細胞は、3空間白血病細胞の亜集団(一時停止(S)、位相明るい(PB)、および位...
病気の再発に寄与する微小残存病変(MRD)は、積極的な難治性ALLの治療、ならびに、他の血液悪性腫瘍のホストに主要な臨床課題であり続けています。骨髄微小環境は、ALL 3,8における再発の最も一般的な部位です。このように、骨髄微小環境をモデル化したモデルは、化学療法の露光中にMRDの白血病腫瘍細胞の生存および維持に関連する仮説をテストするための重要なツールです。?...
The authors have no competing financial interests.
Supported by National Institutes of Health (NHLBI) R01 HL056888 (LFG), National Cancer Institute (NCI) RO1 CA134573NIH (LFG), P30 GM103488 (LFG), WV CTR-IDEA NIH 1U54 GM104942, the Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program, and the WV Research Trust Fund. We are grateful for the support of Dr. Kathy Brundage and the West Virginia University Flow Cytometry Core Facility, supported by NIH S10-OD016165 and the Institutional Development Award (IDeA) from the NIH Institute of General Medical Sciences of the National Institutes of Health (CoBRE P30GM103488 and INBRE P20GM103434).
Name | Company | Catalog Number | Comments |
G10 sephadex beads | Sigma | G10120 | Referred to in manuscript as gel type 10 cross-linked dextran particles |
10 ml sterile syringe | BD | 309604 | |
Glass wool | Pyrex | 3950 | |
1-way stopcocks | World Precision Instruments, Inc. | 14054-10 | |
50 ml conical centrifuge tubes | World Wide Medical Products | 41021039 | Used as collection tubes |
15 ml conical centrifuge tubes | World Wide Medical Products | 41021037 | Used for cell collection |
Fetal Bovine Serum | Sigma | F6178 | |
0.05% Trypsin | Mediatech, Inc. | 25-053-CI | |
100 x 20 mm Cell Culture Dishes | Greiner Bio-One | 664160 | |
Culture media | |||
Osteoblast culture media | PromoCell | C-27001 | For human osteoblast media |
RPMI 1640 media | Mediatech, Inc. | 15-040 | For tumor media prepation |
Cell lines | |||
Adherent Cells: | |||
Human Osteoblasts | PromoCell | C-12720 | Human osteoblast were cultured according to the supplier’s recommendations. |
Human Bone Morrow Stromal Cells | WVU Biospecimen Core | De-identified primary human leukemia and bone marrow stromal cells (BMSC) were provided by the Mary Babb Randolph Cancer Center (MBRCC) Biospecimen Processing Core and the West Virginia University Department of Pathology Tissue Bank. BMSC cultures were established as previously described (*) | |
Leukemic Cells: | |||
REH | ATCC | ATCC-CRL-8286 | REH cells were cultured according to the supplier’s recommendations and recommended media. |
SD-1 | DSMZ | ACC 366 | SD-1 were cultured according to the supplier’s recommendations and recommended media. |
(*) Gibson LF, Fortney J, Landreth KS, Piktel D, Ericson SG, Lynch JP. Disruption of bone marrow stromal cell function by etoposide. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 1997 Aug;3(3):122–32. |
このJoVE論文のテキスト又は図を再利用するための許可を申請します
許可を申請This article has been published
Video Coming Soon
Copyright © 2023 MyJoVE Corporation. All rights reserved